文献速递头颈外科

中性粒细胞与淋巴细胞比值作为头颈癌预后指标的系统评价与荟萃分析

Neutrophil-to-lymphocyte ratio as a prognostic indicator in head and neck cancer: A systematic review and meta-analysis.
PubMed 文献 · Head Neck · 2018-05-14

该系统评价与荟萃分析旨在探讨中性粒细胞与淋巴细胞比值(NLR)与头颈癌预后的关系。汇总数据显示,NLR升高显著预测较差的总生存期(OS)和疾病特异性生存期(DSS)。

要点

  • 治疗前NLR升高是头颈癌的预后标志物。
  • NLR升高显著预测较差的总生存期和疾病特异性生存期。
  • NLR简单易得,可用于分层高风险患者以考虑辅助治疗。

核心结论

  • 治疗前NLR升高是头颈癌的预后标志物,代表一种简单易得的标志物,可用于分层可能从辅助治疗中获益的高风险患者。

主要发现

  • 汇总数据显示,NLR升高显著预测较差的总生存期(OS)和疾病特异性生存期(DSS)。

临床怎么用

  • 治疗前NLR可作为头颈癌预后评估的简单指标,有助于识别高风险患者并考虑辅助治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purposes of this systematic review and meta-analysis were to investigate the relationship between the neutrophil-to-lymphocyte ratio (NLR) and prognosis in head and neck cancer. METHODS: A systematic review and meta-analysis were done to investigate the role of NLR in overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), and progression-free survival (PFS). RESULTS: For qualitative analysis, 33 cohorts with over 10 072 patients were included. For quantitative analysis, 15 studies were included with 5562 patients. The pooled data demonstrated that an elevated NLR significantly predicted poorer OS and DSS. CONCLUSION: An elevated pretreatment NLR is a prognostic marker for head and neck cancer. It represents a simple and easily obtained marker that could be used to stratify groups of high-risk patients who might benefit from adjuvant therapy.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Tham T, Bardash Y, Herman SW, et al. Neutrophil-to-lymphocyte ratio as a prognostic indicator in head and neck cancer: A systematic review and meta-analysis. Head Neck. 2018. PMID: 29761587. doi:10.1002/hed.25324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。